News
GSK
52.81
+0.59%
0.31
GSK PLC - HOLDING(S) IN COMPANY
Reuters · 17h ago
Weekly Report: what happened at GSK last week (0622-0626)?
Weekly Report · 20h ago
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
TipRanks · 21h ago
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback
Barchart · 21h ago
GlaxoSmithKline (GSK) Gets a Sell from Barclays
TipRanks · 1d ago
GSK’s Extended Salford Lung Study: What a Terminated Data Project Still Means for Investors
TipRanks · 3d ago
Dodge & Cox lifts GSK stake above 5% as institutional backing grows
TipRanks · 3d ago
GSK PLC - HOLDING(S) IN COMPANY
Reuters · 3d ago
Record-setting healthcare M&A activity to extend through H2: PwC
Seeking Alpha · 4d ago
GSK Advances BALANCE Trial: New IBS Drug Candidate Moves Through Mid‑Stage Testing
TipRanks · 4d ago
GSK’s MODIFY Asthma Trial: Early Biologic Bet With Long-Term Upside Potential
TipRanks · 4d ago
Is GSK Quietly Becoming An Oncology Powerhouse
Seeking Alpha · 4d ago
Bernstein Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
TipRanks · 5d ago
US military requires flu vaccine for some after outbreak in Texas training center
Reuters · 5d ago
GSK Revamps Belantamab Dosing in New Multiple Myeloma Study: What Investors Should Watch
TipRanks · 5d ago
GSK announces commencement of tender offer to acquire Nuvalent
TipRanks · 5d ago
BRIEF-GSK Announces Tender Offer To Acquire Nuvalent
Reuters · 5d ago
Moderna: From Buy To Sell After 128.2% Surge (Rating Downgrade)
Seeking Alpha · 6d ago
Moderna: The Comeback Is Now In Full Swing
Seeking Alpha · 6d ago
Same Stock. Better Return. How STHH Quietly Outperformed STM Without Doing Anything Different
TipRanks · 6d ago
More
Webull provides a variety of real-time GSK stock news. You can receive the latest news about GSK PLC through multiple platforms. This information may help you make smarter investment decisions.
About GSK
GSK plc is a United Kingdom-based biopharma company. The Company’s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The Company also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).